KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)DivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Change in Account Payables (2020 - 2025)

Historic Change in Account Payables for Recursion Pharmaceuticals (RXRX) over the last 6 years, with Q3 2025 value amounting to -$5.9 million.

  • Recursion Pharmaceuticals' Change in Account Payables fell 28929.28% to -$5.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 million, marking a year-over-year increase of 15424.15%. This contributed to the annual value of $6.4 million for FY2024, which is 75197.57% up from last year.
  • Recursion Pharmaceuticals' Change in Account Payables amounted to -$5.9 million in Q3 2025, which was down 28929.28% from -$4.8 million recorded in Q2 2025.
  • In the past 5 years, Recursion Pharmaceuticals' Change in Account Payables registered a high of $8.1 million during Q4 2024, and its lowest value of -$5.9 million during Q3 2025.
  • Moreover, its 5-year median value for Change in Account Payables was $71000.0 (2021), whereas its average is $101315.8.
  • As far as peak fluctuations go, Recursion Pharmaceuticals' Change in Account Payables skyrocketed by 579090.91% in 2021, and later tumbled by 148873.24% in 2022.
  • Quarter analysis of 5 years shows Recursion Pharmaceuticals' Change in Account Payables stood at -$3.5 million in 2021, then surged by 119.82% to $695000.0 in 2022, then crashed by 145.61% to -$317000.0 in 2023, then skyrocketed by 2662.15% to $8.1 million in 2024, then plummeted by 172.52% to -$5.9 million in 2025.
  • Its last three reported values are -$5.9 million in Q3 2025, -$4.8 million for Q2 2025, and $3.7 million during Q1 2025.